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Abstract
As meat is a rich source of the omega-3 fatty acid docosapentaenoic acid (DPA) and Australians
consume 6 times more meat than fish, investigation of the potential health benefit of DPA is
warranted. The aims were to compare the effects of seal oil supplementation with fish oil, on
measures of plasma lipids and blood pressure in hypertriglyceridaemic subjects. Forty-eight
volunteers were recruited from the Wollongong community and were randomly allocated to one of
three groups receiving 1g/d of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA)
using one of three oils: seal oil capsules (340mg eicosapentaenoic acid (EPA), 230mg DPA, 450mg
DHA), fish oil capsules (210mg EPA, 30mg DPA, 810mg DHA) or placebo capsules (containing
sunola oil) for 6 weeks. Plasma triglycerides remained unchanged in the placebo group, whilst
reductions of 7% and 14% (p<0.05) were seen in the fish oil and seal oil groups respectively.
Systolic blood pressure improved by 8 and 5 mmHg with seal oil and fish oil respectively (p<0.05).
The mean arterial pressure was significantly lower after seal oil supplementation (p<0.005)
compared with the placebo group. These results indicate that seal oil is as effective as fish oil in
lowering plasma triglycerides and blood pressure.

Keywords: Docosapentaenoic acid, omega-3 polyunsaturated fatty acids, cardiovascular disease,
blood pressure, dyslipidaemia
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Introduction

Cardiovascular disease (CVD) is the greatest single cause of mortality in Australia, accounting for
34% and 39% of male and female deaths, respectively (1). Numerous clinical trials have shown
that highly unsaturated long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) such as
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) benefit
cardiovascular disease outcomes in primary and secondary prevention (2). Risk factors for CVD
include hypertension and dyslipidaemia, with increased plasma triglycerides emerging as an
independent risk factor (3). EPA and DHA are effective in lowering plasma triglyceride levels (4).
Yet there is almost no data available regarding the potential health benefits of the only other
common highly unsaturated LC n-3 PUFA, docosapentaenoic acid (DPA; 22:5n-3).

Epidemiological evidence indicates that intakes of all three of the LC n-3 PUFA (EPA, DHA,
DPA) are significantly and inversely related to carotid intimal-medial thickness (IMT) (5). The
quartiles of gram EPA intakes (0.00-0.15; 01.6-0.29; 0.30-0.41; 0.42+); of gram DHA intakes
(0.01-0.27;0.28-0.45; 0.46-0.63; 0.64+) and of gram DPA intakes (0.02-0.04; 0.05-0.07; 0.08-0.10;
0.11+) all correlated with negatively with IMT, which suggests that the cardiovascular benefits
attributed to LC n-3 PUFA are not just attributable to EPA and DHA, but also to DPA (5).
Furthermore, the Kuopio Ischaemic Heart Disease Risk Factor Study showed that the men with the
highest quintile of serum DHA plus DPA (>3.58% of total fatty acids) had a 44% reduced risk of
acute coronary events compared with men in the lowest quintile (<2.38% of total fatty acids), and
there were no associations with EPA levels (6). The significance was due to DHA plus DPA, not
just DHA alone. Hence there is scientific evidence that DPA has cardiovascular health benefits
but this evidence is limited.
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DPA can be found in relative abundance in most red meat. Australian grass fed beef contains 32mg
EPA, 49mg DPA and 6mg DHA per 100g lean beef, as opposed to grain fed beef which contains
much lower values (16mg EPA, 37mg DPA and 5mg DHA per 100g) (7). This is consistent with
beef from USA with range fed beef containing 0.62% EPA, 0.71% DPA and 0.09% DHA as percent
of total fatty acids compared with only 0.13% EPA, 0.26% DPA and 0.04% DHA in feed-lot (grain
fed) beef (8). Hence meat contains more DPA and EPA, whereas fish/seafood contains more DHA
and much less DPA.

Actual DPA intakes have been reported as 90mg/d for men and 52mg/d for women in Australia (9)
which is comparable to that of France (75mg/d for men and 56mg/d for women, (10)) and Japan
(90mg/d for both men and women in Japan (5)), but both France and Japan consume more
fish/seafood than Australians and hence their EPA and DHA intakes are higher than Australian
intakes (5,9,10). As Australians consume more meat than fish/seafood, in the Australian diet, meat
contributes up to 42.7% of LC n-3 PUFA intake which is similar to the new estimate of fish and
seafood of 48% (9,11). This would indicate that DPA intakes are 3-fold higher than previously
thought (9,11). Importantly, DPA intakes contribute up to 30% towards the intakes of LC n-3
PUFA in the Australian adult diet (9). Given this level of DPA in the Australian diet, it is pertinent
to understand its potential health benefit.

However for research studies on DPA, no purified or enriched form is commercially available. The
richest commercial source of DPA is seal oil. There have been limited trials assessing the effect of
seal oil supplementation on cardiovascular disease risk factors. One study showed a significant
reduction in plasma triglycerides after seal oil supplementation for 6 weeks in healthy people (12),
whilst another similar study showed no significant lowering of plasma triglycerides (13). However
these studies were conducted in people with normal plasma triglyceride levels. Therefore the aim
of this study was to assess the ability of seal oil supplementation to lower plasma triglyceride levels
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and blood pressure in people with hypertriglyceridaemia in comparison to fish oil containing similar
levels of EPA and DHA in a placebo controlled double blind intervention trial.
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Experimental Procedures

Notification of Clinical Trial and Ethics Approval
The study on the cardiovascular effects of DPA was registered with the Australian Clinical Trial
Register, number ACTRNO12605000641695 and notification forwarded to the Therapeutics Goods
Administration. Ethics approval was granted from the University of Wollongong (UoW) Human
Research Ethics Committee and informed consent was obtained from all study participants prior to
commencement of the clinical trial.

Recruitment and study population
Hypertriglyceridaemic subjects were recruited via newspaper advertisements, email to UoW
community, social clubs and on local ABC radio. The UoW media release unit also generated
interest from the media. Fifty-six volunteers were recruited and eligible for the study (i.e. plasma
triglycerides > 1.5mmol/L) and 48 completed the study. Reasons for dropping out of the study
included suffering from diarrhoea, forgetting to come to their 6 week appointment, losing their job
and not being contactable for their 6 week appointment or no reasons at all. People already taking
fish oil supplements were excluded from the study.

Seal Oil, Fish Oil and Placebo Capsule Supplementation
The capsules were 500mg in weight and the composition is shown in table 1. All 3 groups were
provided with two separate bottles of capsules and they were asked to take 10 capsules per day; 4
capsules before breakfast and 6 capsules before dinner, such that all 3 groups were taking the same
number of capsules per day. The target LC n-3 PUFA intake of the Seal Oil (BGI Atlantic Marine
Product Inc, Canada) and Fish Oil (NuMega Ingredients Ltd, Sydney) groups was 1g/day.
Therefore the Seal Oil group took 10 Seal Oil capsules per day (which provided 340mg EPA,
230mg DPA, 450mg DHA per day); the Fish Oil group took 4 placebo capsules and 6 Fish Oil
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capsules per day (which provided 210mg EPA, 30mg DPA, 810mg DHA per day). The third group
took 10 placebo capsules per day (Sunola oil, NuMega Ingredients Ltd, Sydney, which provided no
LC n-3 PUFA but did provide approximately 4g monounsaturated oil per day). The placebo group
intake of monounsaturated oil in quantity is trivial compared to the dietary intake of
monounsaturated fat. Furthermore as the seal oil capsules contained squalene (12.5mg/500mg
capsule), the fish oil and placebo groups took one squalene capsule (875mg) per week for 6 weeks
equivalent to 125mg/day, an identical intake to the seal oil group. Seal oil provided a 7.6 fold
increase in the amount of DPA; a 1.6 fold increase in the amount of EPA and a 1.8 fold decrease in
the amount of DHA compared to fish oil (Table 1B).
Seal oil also contains 0.3mg/100g vitamin A and 4.5mg/100g alpha-tocopherol (14). Tuna oil
contained less than 10 International Units of vitamin A and 0.21% of mixed natural tocopherols
(NuMega Ingredients Ltd, Sydney).

Study Design
A randomised, parallel, placebo controlled, double blind study was conducted in 56
hypertriglyceridaemic subjects, with 48 who completed the study. They were randomly allocated to
one of three groups and all three groups took ten 500mg capsules per day for a 6 week intervention
trial. Blood pressure and fasting blood samples were taken at baseline and at 6 week post
intervention. Blood samples were assessed for erythrocyte fatty acids and plasma lipids
(triglycerides, total cholesterol, LDL-cholesterol and HDL-cholesterol).

Erythrocyte Fatty Acids
Fasting blood samples were collected into tubes containing ethylenediamine tetra-acetic acid
(EDTA) and placed on ice. The erythrocytes were separated from plasma by centrifugation (10
min, 2000g, 4°C). Erythrocyte and plasma samples were stored at -80°C until analysed.
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Erythrocyte membranes were isolated from 400l of packed erythrocytes and prepared for fatty acid
analysis. The erythrocytes were lysed in 10ml TRIS buffer (10mM TRIS buffer, 2mM EDTA, pH
7.2) and the membranes were pelleted after ultracentrifugation (200000 g, 4°C, 30 minutes). The
erythrocyte membrane pellets were resuspended in 200l water and 150l was transferred into glass
tubes for direct transesterification as described by Lepage and Roy (15). Briefly, 2ml of methanol:
toluene (4:1) was added to each sample. While vortexing, 200µl of acetyl chloride was added drop
wise to each sample using a positive displacement pipette. Samples were then heated for 60
minutes at 100°C in a heating block. After the tubes had been cooled in cold water, 3ml of
potassium chloride (10%) and 100µl of toluene were added to each tube before centrifugation for 10
minutes (2000g, 4°C). The fatty acid methyl esters, contained in the upper toluene phase, were
removed and placed into GC vials. The fatty acid methyl esters were analysed by flame-ionisation
gas chromatography (model GC-17A, Shimadzu) using a 30m x 0.25mm internal diameter capillary
column (Varian). Individual fatty acids were identified upon comparison with known fatty acid
standards (NuChek, Sigma, Australia, mix C10-C24 plus added DPA).

Plasma Lipids
HDL was isolated from plasma by precipitation of the apoB containing lipoproteins using dextran
sulphate and magnesium chloride according to Warnick et al (16). All lipid analyses (plasma
triglyceride, total cholesterol, HDL-cholesterol) were carried out using enzymatic colorimetric
assays using the Konelab autoanalyser. LDL-cholesterol was calculated using the Friedewald
calculation (17).

Blood Pressure
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP)
were measured using the Omron blood pressure instrument (Medisave Australasia). These
measurements were taken in triplicate at baseline (duplicate days) and after 6 weeks intervention
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(duplicate days). An average of the 6 baseline readings were obtained for each study participant
and similarly after 6 weeks intervention.

Statistical analysis
Statistical analysis was carried out using JMP statistical analysis package (SAS Institute Inc
Windows NT v5.1) and where variables were not normally distributed (plasma triglycerides), log
transformation was used prior to analysis. One way ANOVA was used to assess the change in
plasma triglycerides and blood pressure between the three groups. One way ANOVA was also used
to assess the change in erythrocyte EPA and DHA levels and the change in plasma triglycerides per
group. Pearson correlation analyses were conducted using Microsoft Excel. Statistical significance
was set at α = 0.05 for all analyses.
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Results

Study Participant Characteristics and Baseline Blood Pressure and Plasma Lipids (Table 2)
The study participant baseline characteristics and baseline blood pressure and plasma lipids are
shown in Table 2. There were no significant differences in age, sex, weight, body mass index
(BMI) and blood pressure lowering medication used, between the three groups at baseline. On
average the study population was overweight, and ranging from middle age to elderly. All subjects
were hypertriglyceridaemic, but with relatively normal plasma cholesterol levels. Systolic blood
pressures were greater than 140mmHg in 23% of the study population whilst diastolic blood
pressures were greater than 90mmHg in 10% of the study population. The study volunteers did not
change their body weight throughout the intervention (results not shown).

Erythrocyte Fatty Acids (Table 3 and figure 1)
The main erythrocyte LC PUFA measured at baseline (0 weeks) and after 6 weeks of intervention
(week 6) in all 3 groups are shown in Table 3. The placebo group showed no changes over the 6
weeks period. In comparison to its own baseline value (0 weeks), fish oil supplementation resulted
in decreases in arachidonic acid (AA, 20:4n-6, (p<0.01), adrenic acid (22:4n-6, p<0.05) and DPA
(22:5n-3, p<0.05) and an increase in DHA (22:6n-3, p<0.01). In comparison to its own baseline
value (0 weeks), seal oil supplementation significantly decreased levels of AA (p<0.05) and adrenic
acid (p<0.05) and significantly increased the mean levels of EPA (p<0.001), DPA (p<0.001) and
DHA (p<0.0005).

Figure 1 shows the comparison of the percentage changes in erythrocyte fatty acids in the three
groups after 6 weeks supplementation. In comparison to the change in the placebo group (0-6
weeks), there were no significant difference in AA, EPA and DPA in the fish oil group (0-6 weeks),
but there were significant decreases in adrenic acid (p<0.05) and increases in DHA (p<0.0005). In
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comparison to the change in the placebo group (0-6 weeks), there was no significant difference in
AA in the seal oil group (0-6 weeks), but there were significant decreases in adrenic acid (p<0.05)
and significant increases in EPA (p<0.001), DPA (p<0.001) and DHA (p<0.0001).

Plasma Lipids (Figure 2)
The change in plasma lipids (mmol/L) from baseline (0 weeks) to 6 weeks for all 3 groups are
shown in Figure 2. Plasma triglycerides remained unchanged in the placebo group (2.31 versus
2.36mmol/L), but were reduced by 7% in the fish oil group (2.24 versus 2.09mmol/L, p>0.05) and
14% in the seal oil group (2.54 versus 2.19mmol/L) (p<0.05) and these changes were significantly
different to the changes in the placebo group. No differences were seen in the total cholesterol,
LDL-cholesterol or HDL-cholesterol between any of the groups.

Blood Pressure (Figure 3)
The changes in blood pressure results are shown in figure 3. Systolic blood pressure (SBP)
decreased significantly in both the fish oil (-5.3mmHg, p<0.05) and the seal oil groups (-7.7mmHg,
p<0.01) in comparison to the placebo group (6mmHg). The mean arterial pressure (MAP) was
significantly reduced (-8.3mmHg, p<0.01) in the seal oil group and tended towards a reduction (3.5mmHg, n.s.) in the fish oil versus the placebo group (3.9mmHg). There were no statistical
differences in diastolic blood pressure (DBP) in the three groups.

Correlations between the change in erythrocyte EPA and DHA levels and the change in plasma
triglycerides and blood pressure (Table 4)
The change in erythrocyte EPA+DHA levels correlated with the change in plasma triglycerides in
the seal oil group, r=0.52 (p<0.05) but there were no correlations in the fish oil or placebo oil
groups with the change in plasma triglycerides (Table 4).
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There were several significant correlations (see Table 4) between the change in erythrocyte EPA
and DHA levels and the change in SBP, DBP and MAP in the fish oil groups with correlation coefficients ranging from 0.56 to 0.76, (p<0.05). As expected there were no correlations with
erythrocyte LC n-3 PUFA and blood pressure in the placebo group (Table 4).
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Discussion

The supplementation of 1g of LC n-3 PUFA per day supplied by fish oil capsules for 6 weeks
resulted in a significant increase in erythrocyte DHA levels, which is in agreement with previous
studies using similar doses of fish oil and similar duration of intervention (18,19). However, the
supplementation of 1g of LC n-3 PUFA per day supplied by seal oil capsules for 6 weeks differed
to that of fish oil, in that DPA and EPA in addition to DHA were significantly increased, which is
in agreement with a previous study using the same 1g dose of seal oil for 6 weeks (12).

It has been shown previously that intakes of EPA and DHA correlate significantly with erythrocyte
EPA and DHA levels respectively (20). However, there was no correlation between DPA intakes
and erythrocyte DPA levels (correlation coefficient r = 0.05, p=0.71), despite quite reasonable
correlations between dietary intakes and erythrocyte levels of EPA, DHA and total LC n-3 PUFA
(20). Since that publication, another study assessed the validity of a PUFA questionnaire by
comparison to 3 day weighed food record and erythrocyte fatty acids using the methods of triads
(21). In that triangulation of DPA intakes from PUFA questionnaire versus DPA intake from 3 day
weighed food record versus DPA in erythrocytes (or plasma) - a validity co-efficient could not be
determined as the estimate was >1 for erythrocytes and negative for plasma. This lack of
correlation between dietary intake of DPA and circulating levels of DPA has been shown by
another group (22) who assessed a different questionnaire. Using the methods of triads they found
a similar negative validity co-efficient when assessing plasma DPA to their questionnaire and
weighed food records (22). Hence whilst there is a direct correlation between EPA and DHA
intakes and EPA and DHA erythrocyte levels respectively, this does not hold true for DPA as there
is no direct correlation between DPA intake and erythrocyte or plasma levels of DPA.
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Therefore to interpret the DPA results in this study it is probably better to look at DPA intakes
rather than erythrocyte levels of DPA. In this study the fish oil group consumed 210mg/d EPA,
30mg/d DPA and 810mg/d DHA, whilst the seal oil group consumed 340mg/d EPA, 230mg/d DPA
and 450mg/d DHA. The difference between the fish oil and seal oil groups is the seal oil group
consumed 130mg/d more EPA; 200mg/d more DPA and 360mg/d less DHA than the fish oil group.
This difference corresponds to a 1.6 fold increase in EPA; a 7.6 fold increase in DPA and a 1.8 fold
decrease in DHA, where the magnitude of dietary change is greatest in DPA.

This study showed a trend towards a 7% reduction plasma triglyceride levels with 1g LC n-3
PUFA per day fish oil supplementation, which is less than a recently published study that assessed
a dose response with DHA rich fish oil supplementation which showed 6% (n.s.), 20% and 25%
reductions with approx 0.7g, 1.3g and 2g of fish oil supplementation per day for 6 weeks (19). The
seal oil 1g LC n-3 PUFA per day supplementation for 6 weeks resulted in 14% reduction in plasma
triglyceride which was also less than 21% reduction previously reported (12), however another seal
oil study showed no significant lowering of plasma triglycerides (13). Both Bonefeld-Jorgensen et
al (12) and Conquer et al (13) were conducted in healthy people with normal plasma triglyceride
levels which could explain the lack of effect in the latter study. The Bonefeld-Jorgensen et al study
(12) was not a placebo controlled study and the reductions in plasma triglyceride seen could have
been due to other factors.

In terms of the mechanism in plasma triglyceride lowering effect, a decrease in hepatic VLDL
output has been attributed to increased hepatic fatty acid oxidation and a decreased rate of
lipogenesis (23,24). EPA and DHA have been shown to be ligands for nuclear receptors such as
PPAR-alpha (23,24,25) and sterol regulatory element binding proteins (23,26), which modulate the
expression of key genes in these metabolic processes. Now DPA may also be involved in these
processes. Certainly in a well controlled rat study (where seal oil and fish oil supplemented rat
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groups had constant PUFA/MUFA/SAFA levels and the control rat group had linoleic acid as their
sole PUFA in the diet), the seal oil was more effective than fish oil in lowering serum triglyceride
levels (27).

In this rat model the activities of fatty acid synthase, glucose-6-phosphate

dehydrogenase and hepatic lipase were all lower in the seal oil group compared to the control
group, whereas only the activity of hepatic lipase was lower in the fish oil group compared to the
control group. However, the activities of peroxisomal beta-oxidation and lipoprotein lipase in
adipose tissue were significantly higher in the fish oil group compared to the controls (27). Hence
the hypotriglyceridaemic effect of the seal oil was attributed to suppression in fatty acid synthesis.
As the main difference between seal oil and fish oil is the 8 fold increased level of DPA in seal oil,
the authors surmised that this higher DPA content could be the primary agent responsible for
triglyceride lowering.

Moreover, a study comparing the effects of EPA rich oil versus DHA rich oil on circulating plasma
triglyceride levels in humans found that the DHA rich oil was more effective than EPA rich oil and
remained significant when compared to the olive-oil placebo group, whereas the EPA rich oil did
not (28). Interestingly, the authors pointed out that the DHA rich oil contained a 6 fold greater
amount of DPA than the EPA rich oil, but the hypotriglyceridaemic effect of DPA was unknown
and that it warranted further study (28).

In the present study both fish oil and seal oil supplementation resulted in improvements in blood
pressure.

The reduction in blood pressure as a result of fish oil supplementation are well

documented with several meta-analyses showing benefits as described in the review by Mori (29).
However, most of these trials required doses of 3-4g per day to achieve the blood pressure lowering
benefits. This study showed significant reductions in SBP (fish oil and seal oil groups) and MAP
(seal oil group) but no significant reductions in DBP (all groups) using 1g dose of LC n-3 PUFA
per day for 6 weeks. There was an increase in SBP in the placebo group, however, upon re-
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analysis with estimating zero change in SBP in the placebo group, the changes in SBP in the seal
oil and fish oil groups remained significantly lower compared to placebo.

However the increase in erythrocyte EPA+DHA after fish oil but not seal oil supplementation
correlated with the change in blood pressure. EPA correlated with SBP whilst DHA correlated
with DBP (Table 4).

Mori et al (30) showed that purified DHA capsules lowered 24 hour

ambulatory blood pressure in mild hyperlipidaemic subjects, whilst purified EPA capsules had no
effect. Even though similar study populations were assessed, it is not clear why the differential
effect of EPA on SBP and DHA on DBP is seen in this current study. However, other studies have
shown limited effect of EPA and DHA on blood pressure in normotensive people (31) and in study
populations taking multiple medications (29).

Even though there was no correlation between the changes in erythrocyte EPA+DHA levels and
the change in blood pressure in the seal oil treated group, in this study, seal oil resulted in a
significant 8mmHg reduction in SBP. Usually high doses of EPA+DHA of 3-4g per day are
needed to reduce blood pressure as shown by meta-analyses (32,33). It is conceivable that the
significant reduction in SBP in the current study could be due to 1) the study population having an
average blood pressure of 130/75mmHg of which 23% had SBP greater than 140mmHg and 10%
had DBP greater than 90mmHg and 2) less than 20% of the study population were taking
medication to lower their blood pressure, thereby allowing the omega-3 PUFA to be effective. A
study by Vericel et al (34) showed that supplementation for 42 days with 150mg DHA and 30mg
EPA per day in an elderly un-medicated population resulted in 14mmHg reduction in SBP, which
is consistent with the current study showing the effect of low dose omega-3 PUFA and reduction in
SBP.
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The mechanisms of action of LC n-3 PUFA on blood lowering effects have been described by Mori
et al (29). The mechanisms include 1) the LC n-3 PUFA having vasodilatory effects by increasing
the release of nitric oxide; 2) modifying the release of ADP, vasoactive prostanoids (such as
thromboxane A2 and prostacyclin I2) 3) and the LC n-3 PUFA incorporation into plasma and
cellular membranes, altering the physicochemical structure of the membrane and leading to changes
in fluidity, permeability and function of the membrane and membrane-bound proteins (29).

Given the health benefits of seal oil containing DPA, what are some DPA rich containing foods?
Australian red meat is a relatively rich source of DPA (9,11) and Australians consume six times
more meat (158g per day (35), 164g per day (36)) than fish/seafood (26g per day (35), 28g per day
(36)). Abalone is another DPA rich food (37) but the consumption is also much lower than meat.
The National Health and Medical Research Council (NHMRC) in Australia has released Nutrient
Reference Values (NRV) for LC n-3 PUFA intakes which includes EPA, DPA and DHA (38).
However, DPA is not included in the LC n-3 PUFA nutrient claim in the current Food Standards
Australia and New Zealand (FSANZ) Code (39). The exclusion of DPA precludes many cuts of
meat qualifying for this LC n-3 PUFA nutrient claim. Hence these standards favour fish and
seafood as well as fortified foods containing LC n-3 PUFA over those with intrinsic DPA content
(40). The rationale for the exclusion of DPA is a lack of scientific evidence. Hence more research
is warranted to ascertain the potential health benefits of DPA. Therefore larger trials with more
pure forms of DPA are warranted.

In conclusion, 1g/d of LC n-3 PUFA from seal oil is just as effective as 1g/d of LC n-3 PUFA from
fish oil in reducing plasma triglyceride levels and SBP in hypertriglyceridaemic subjects; however,
studies using (as yet unavailable) purified DPA are warranted.
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Figure legends

Figure 1
The percent change in erythrocyte fatty acids (6 weeks minus baseline) from the three groups from
left to right: placebo, fish oil and seal oil group. The fatty acid abbreviations: 20:5n-3 is
eicosapentaenoic acid, 22:5n-3 is docosapentaenoic acid, 22:6n-3 is docosahexaenoic acid, 20:4n-6
is arachidonic acid and 22:4n-6 is adrenic acid.
* significantly different from the change in the placebo group (p<0.05).

Figure 2
The change in plasma lipids (mmol/L) in the three groups from left to right: placebo, fish oil and
seal oil group. Plasma lipid abbreviations: TG triglycerides, TC total cholesterol, LDL-C low
density lipoprotein cholesterol and HDL-C high density lipoprotein cholesterol.
* significantly different from the change in the placebo group (p<0.05)

Figure 3
The change in blood pressure (mmHg) in the three groups from left to right: placebo, fish oil and
seal oil group. Blood pressure abbreviations; SBP systolic blood pressure, DBP diastolic blood
pressure and MAP mean arterial pressure
* significantly different from the change in the placebo group (p<0.05)
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Table 1A Individual capsule composition by principal fatty acid (mg per 500mg capsule).
Fatty acid

Sunola Oil Capsules

Fish Oil Capsules

Seal Oil Capsules

(mg/500mg)

(mg/500mg)

(mg/500mg)

C18:1n-9

425

61

142

C20:5n-3

0

35

34

C22:5n-3

0

5

23

C22:6n-3

0

135

45

Table 1B Amount of principal fatty acids supplemented per group per day (mg per day)

Fatty acid

Sunola Oil Group

Fish Oil Group

Seal Oil Group

(placebo)

(mg per day)

(mg per day)

(mg per day)
C18:1n-9

4250

1944

1420

C20:5n-3

0

210

340

C22:5n-3

0

30

230

C22:6n-3

0

810

450

Total LC n-3 PUFA

0

1050

1020

Placebo group consumed 10 placebo capsules per day; Fish Oil group consumed 6 fish oil capsules
per day plus 4 placebo capsules per day; Seal Oil group consumed 10 seal oil capsules per day
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Table 2 Study Participant Characteristics, plasma lipids and blood pressure at baseline (n=48)

Placebo

Fish Oil

Seal Oil

(n=17)

(n=15)

(n=16)

9/8

6/9

9/7

57 + 7 a

59 + 7

54 + 7

(42-70)

(49-73)

(45-69)

86 + 12

79 + 18

79 + 11

(63-114)

(53-108)

(62-107)

Body Mass Index

29 + 3

28 + 5

27 + 3

(kg/m2)

(25-37)

(19-36)

(22-34)

Plasma triglycerides

2.31 + 0.73

2.24 + 0.18

2.54 + 0.27

(mmol/L)

(1.69-3.61)

(1.57-3.67)

(1.57-5.26)

Total cholesterol

5.14 + 0.22

5.31 + 0.18

5.60 + 0.25

(mmol/L)

(3.61-6.52)

(3.68-6.82)

(4.13-6.67)

LDL-cholesterol*

3.06 + 0.18

3.38 + 0.18

3.63 + 0.22

(mmol/L)

(1.93-4.23)

(2.34-4.40)

(2.41-4.83)

HDL-cholesterol

1.12 + 0.07

1.12 + 0.10

1.03 + 0.05

(mmol/L)

(0.75-1.91)

(0.63-1.90)

(0.65-1.34)

Systolic Blood

126 + 13

131 + 14

137 + 21

Pressure (mmHg)

(99-151)

(100-147)

(119-189)

Diastolic Blood

73 + 9

74 + 11

79 + 9

Pressure (mmHg)

(60-85)

(57-93)

(70-92)

Mean Arterial

93 + 10

95 + 10

102 + 14

Pressure (mmHg)

(73-107)

(77-106)

(88-129)

Male/Female (n)

Age (years)

Weight (kg)

27

Blood pressure
medication (M/F)

2/1

2/2

n is number of participants as males and females
a

Values are mean  SD (range)

*LDL-C was calculated using the Friedewald calculation (17)

0/2
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Table 3 Red Blood Cell Fatty Acids (expressed as % of total fatty acids)

20:4n-6

22:4n-6

20:5n-3

22:5n-3

22:6n-3

0 weeks

12.80.3a

2.30.1

1.10.1

2.50.1

5.00.2

6 weeks

12.50.3

2.30.1

1.10.1

2.40.2

5.00.2

0 weeks

12.60.2

2.50.2

1.10.2

2.60.1

5.20.3

6 weeks

12.10.2**

2.10.1*

1.30.1

2.40.1*

6.40.3***

0 weeks

12.60.2

2.20.1

1.00.1

2.50.1

4.80.2

6 weeks

12.00.2*

2.00.2*

1.80.1****

2.70.1****

5.80.1***

Placebo
(n=17)

Fish Oil
(n=13)

Seal Oil
(n=16)

a

Values are mean  SEM

* p<0.05, ** p<0.01, *** p<0.005, ****p<0.0001, differences between 0 and 6 weeks
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Table 4 Correlations between the changes in erythrocyte LC n-3 PUFA and changes in plasma
triglyceride and changes in blood pressure.

Change in

Placebo

Fish Oil

Seal Oil

(n=17)

(n=15)

(n=16)

r

r

r

Change in EPA

0.094

0.028

0.283

Change in DPA

-0.106

0.131

-0.210

Change in DHA

-0.127

0.077

0.381

Change in

-0.024

0.067

0.520*

-0.099

0.089

0.442

Change in EPA

0.055

0.634*

-0.165

Change in DPA

-0.270

0.065

0.023

Change in DHA

-0.156

0.451

-0.181

Change in

-0.080

0.556*

-0.282

-0.290

0.558*

-0.264

TG (6-0)

EPA+DHA
Change in
EPA+DPA+DHA
Change in
SBP (6-0)

EPA+DHA
Change in

30

EPA+DPA+DHA
Change in

Change in EPA

-0.201

0.330

-0.190

Change in DPA

0.286

-0.444

0.222

Change in DHA

-0.398

0.756*

0.428

Change in

-0.421

0.714*

0.299

-0.148

0.651*

0.330

Change in EPA

-0.090

0.446

-0.282

Change in DPA

-0.056

-0.010

0.255

Change in DHA

-0.203

0.608*

0.103

Change in

-0.206

0.628*

-0.078

-0.232

0.647*

-0.023

DBP (6-0)

EPA+DHA
Change in
EPA+DPA+DHA
Change in
MAP (6-0)

EPA+DHA
Change in
EPA+DPA+DHA

* p <0.05

1

Figure 1 The percent change in erythrocyte fatty acids (6 weeks minus baseline).
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* significantly different from the change in the placebo group (p<0.05)

2

Figure 2 The change in plasma lipids (mmol/L) in the placebo, fish oil and seal oil groups.
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3

Figure 3 The change in blood pressure (mmHg) in the placebo, fish oil and seal oil groups.
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